These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17106369)

  • 21. Is more always better?
    Tuulonen A
    Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative effectiveness: insights on treatment options for open-angle glaucoma.
    Morse AR; Lee PP
    Arch Ophthalmol; 2012 Apr; 130(4):506-7. PubMed ID: 22491919
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of patients with ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Rosenbaum LJ
    Am J Ophthalmol; 2007 Jan; 143(1):191-2; author reply 192-3. PubMed ID: 17188074
    [No Abstract]   [Full Text] [Related]  

  • 24. [An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients].
    Rouland JF; Peigne G; Sellem E; Renard JP; Williamson W; Filippi JM; Cohn H; Hamard P; Abellan P; Chagnon A; Malet F; Haye I
    J Fr Ophtalmol; 2001 Mar; 24(3):233-43. PubMed ID: 11285438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.
    Oostenbrink JB; Rutten-van Mölken MP; Sluyter-Opdenoordt TS
    J Glaucoma; 2001 Jun; 10(3):184-91. PubMed ID: 11442180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.
    Rouland JF; Berdeaux G; Lafuma A
    Drugs Aging; 2005; 22(4):315-21. PubMed ID: 15839720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
    Walt JG; Lee JT
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S36-44. PubMed ID: 15016560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model.
    Wang JC; Chew PT
    Clin Exp Ophthalmol; 2004 Dec; 32(6):578-83. PubMed ID: 15575827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glaucoma care cost-effectiveness.
    Hoskins HD
    Ophthalmology; 2009 May; 116(5):1016. PubMed ID: 19410965
    [No Abstract]   [Full Text] [Related]  

  • 31. Modelling the lifetime economic consequences of glaucoma in France.
    Philippe Nordmann J; Lafuma A; Berdeaux G
    J Med Econ; 2009 Mar; 12(1):9-16. PubMed ID: 19450060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence.
    Smith AF; Negretti G; Mascaro A; Bokre D; Baker H; Dhalla K; Murdoch IE
    Ophthalmic Epidemiol; 2018; 25(5-6):419-435. PubMed ID: 30059637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effective evaluation of the glaucoma suspect.
    Doshi A; Singh K
    Curr Opin Ophthalmol; 2007 Mar; 18(2):97-103. PubMed ID: 17301609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy.
    Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M
    Curr Med Res Opin; 2005 Nov; 21(11):1837-44. PubMed ID: 16307705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.
    Orme M; Boler A
    Pharmacoeconomics; 2006; 24(8):743-50. PubMed ID: 16898845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.
    van Gestel A; Webers CA; Severens JL; Beckers HJ; Jansonius NM; Hendrikse F; Schouten JS
    Acta Ophthalmol; 2012 Feb; 90(1):20-31. PubMed ID: 22289192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter).
    Kymes S
    J Glaucoma; 2006 Oct; 15(5):471-2; author reply 472-3. PubMed ID: 16988613
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist.
    Peeters A; Schouten JS; Webers CA; Prins MH; Hendrikse F; Severens JL
    Eye (Lond); 2008 Mar; 22(3):354-62. PubMed ID: 17128205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocular hypertension and glaucoma associated with scleritis and uveitis. Aspects of epidemiology, pathogenesis and therapy.
    Schlote T; Zierhut M
    Dev Ophthalmol; 1999; 30():91-109. PubMed ID: 10627919
    [No Abstract]   [Full Text] [Related]  

  • 40. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study.
    Koleva D; Motterlini N; Schiavone M; Garattini L;
    Ophthalmologica; 2007; 221(5):340-7. PubMed ID: 17728557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.